## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.4% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($314.23)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Tema Etfs LLC Has $3.62 Million Stock Holdings in Amgen Inc. $AMGN**
- Source: MarketBeat | 20251205T134359 | Bullish | Relevance: 99%
-  Tema Etfs LLC increased its holdings in Amgen Inc. by 33.3%, now owning 12,977 shares valued at $3.623 million. Amgen reported strong quarterly earnings, beating EPS estimates and achieving a 12.4% revenue increase, while also declaring a $2.38 quarterly dividend. Analysts currently rate Amgen as a "Moderate Buy" with a consensus target price of $335.65.

**2. BMO Capital Raises Price Target for Amgen (AMGN) to $372, Mainta**
- Source: GuruFocus | 20251203T083100 | Bullish | Relevance: 99%
- BMO Capital has raised its price target for Amgen (AMGN) to $372 from $335, reiterating an 'Outperform' rating. This adjustment reflects an 11.04% increase and was issued by analyst Evan David Seigerman on December 3, 2025. The article also provides a summary of recent analyst ratings and Amgen's company profile and product portfolio.

**3. Goldman Sachs Maintains Price Target on Amgen (AMGN) Before Key Trial Readouts**
- Source: Yahoo Finance | 20251203T065700 | Bullish | Relevance: 99%
- Goldman Sachs has reaffirmed its Buy rating and $400 price target for Amgen (AMGN) ahead of anticipated Phase 2 updates for its obesity medication, MariTide. The firm is looking for long-term weight loss with reduced or occasional dosage and minimal gastrointestinal side effects from the maintenance data. MariTide previously demonstrated significant average weight loss in patients with and without Type 2 diabetes, along with improvements in cardiometabolic parameters.

**4. Beutel Goodman & Co Ltd. Raises Position in Amgen Inc. $AMGN**
- Source: MarketBeat | 20251205T084311 | Somewhat-Bullish | Relevance: 99%
-  Beutel Goodman & Co Ltd. increased its stake in Amgen Inc. by 2.7% in the second quarter, now holding 1,436,622 shares valued at $401.1 million, making Amgen its 14th largest holding. Other institutional investors like Vanguard, Geode Capital, Charles Schwab, and Norges Bank also significantly increased their positions, bringing institutional ownership to 76.5%. Amgen recently exceeded Q3 earnings and revenue expectations and declared a quarterly dividend of $2.38.

**5. Guggenheim Capital LLC Boosts Stake in Amgen Inc. $AMGN**
- Source: MarketBeat | 20251204T100837 | Bullish | Relevance: 98%
-  Guggenheim Capital LLC increased its stake in Amgen Inc. by 10.6% in Q2, making it the firm's 28th largest holding. Amgen reported strong Q3 earnings, beating EPS and revenue estimates, and announced a quarterly dividend. The stock maintains a "Moderate Buy" consensus rating with an average price target of $335.65.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |
| 2025-11-14 | Piper Sandler | $381 | $342 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-03 | BMO Capital | main | Outperform |
| 2025-11-14 | Piper Sandler | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.7% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Forward P/E 15.1x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (2 raises, avg +11%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $169.0B |
| Beta | 0.45 |
| 52W Range | $253.30 - $346.38 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 15.1 |
| Current P/E | 15.5 |
| YoY Growth | 2.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -2.7% to -4.4% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.4pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). MACD histogram bearish (-2.05), momentum weakening. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.40% (CS: 10) | Weak |
| RSI_14 | 50.9 | Neutral |
| MACD Histogram | -2.05 | Bearish |
| vs SMA20 | 0.977x | Below |
| vs SMA50 | 1.057x | Above |
| vs SMA200 | 1.112x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $329.89
- **Stop Loss:** $314.23 (4.7% risk)
- **Target:** $345.55 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 31
- **Position Value:** $10,226.59
- **Portfolio %:** 10.23%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*